The psychedelic education and therapy provider Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) has inked a partnership agreement with the educational platform HealingMaps to help promote its clinics and identify new targets for the expansion of its facility portfolio.
The agreement announced on Thursday will enable Numinus to showcase its clinics and services on the HealingMaps platform, a website with an estimated 300,000 visitors monthly. Numinus says it will benefit from market intelligence generated by the platform on the increasing interest in psychedelic-assisted therapy in different areas of North America, which will help the company identify regions with an unmet demand for those therapies.
“At its core, HealingMaps connects people seeking mental health treatment options with trusted and qualified clinics and practitioners in their region, and they’ve established significant traction across our sector,” said Payton Nyquvest, Founder and CEO of Numinus.
HealingMaps has a comprehensive list of ketamine clinics, psilocybin retreats and ibogaine centres and helps people interested in participating in clinical trials with psychedelics connect with researchers conducting them. The platform is based in Miami, Florida.
“We’re honoured to work closely with Numinus going forward, to help identify, analyze and support key markets for expansion, as they look to rapidly grow their clinic footprint and client reach over the next several years,” said Cory Jones, CEO of HealingMaps.
Read more: Optimi Health to supply MDMA for new psychedelic therapy program at Numinus clinics
Read more: Psycheceutical Bioscience develops non-psychoactive ketamine topical for PTSD and depression
Numinus is currently in the midst of developing a new training program for MDMA-assisted therapy in partnership with the Multidisciplinary Association for Psychedelic Studies. The program will allow health practitioners interested in administering the psychedelic to patients to experience and observe therapy sessions with the drug to help improve their understanding of it.
Numinus offers several psychedelic training courses, but this will be the first one to utilize the protocol of MAPS. Pending clinical trial approval from Health Canada, Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) will be supplying the program with its GMP-certified MDMA.
Numinus observed a 581 per cent increase in year-over-year revenue at the end of February this year and generated $4.7 million during Q2 from its network of clinics, a 596.9 per cent increase from the second quarter of 2022.
HealingMaps closed a US$1 million seed funding round last September led by Phyto Partners and Ambria Capital.
Numinus shares shot up by 4 per cent Thursday to $0.26 on the Toronto Stock Exchange and have been on a steady incline over the past month, rising by 62.5 per cent.
rowan@mugglehead.com
